Berjas Abumsimir

Dr. Berjas Abumsimir


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
FRFatima ezzahra Rihane
Fatima ezzahra Rihane
DEDriss Erguibi
Driss Erguibi
OEOthmane Elyamine
Othmane Elyamine
BABerjas Abumsimir
Berjas Abumsimir
MEMOULAY MUSTAPHA ENNAJI
MOULAY MUSTAPHA ENNAJI
FCFarid Chehab
Farid Chehab
Gastric cancer (GC) is one of the leading causes of morbidity and mortality worldwide. The onset and progression of gastric cancer are attributed to numerous triggers, these triggers may be infection of the gastric epithelium by Helicobacter pylori (H. pylori), or by Epstein-Barr virus (EBV). Both agents can establish a lifelong persistent infection in the host, leading to chronic inflammation, which also contributes to cancer development. Objective: The objective of this study is to present the status of co-infection with H. pylori and EBV and the risk of developing adenocarcinoma at an early age in the population of Grand Casablanca. In this study, 100 gastric tissue samples from patients with gastric cancer were examined for detection of H. pylori and EBV in tumor tissue using PCR techniques, and the clinical relevance was statistically analyzed. Results revealed an individual Epstein-Barr virus (EBV) infection observed in (40 %) of gastric carcinoma cases. Furthermore, the frequency of EBV infection was significantly different with intestinal and diffuse gastric cancer types [15 % vs. 85 %; <0.05]. The prevalence of individual H. pylori infections was 34 %, while the frequency of co-infection was 16 %. Moreover, no significant association was found between co-infection and sex, tumor grade, stage, and lymph node metastasis, but there was a significant association between co-infection and the age of GC patients. Thus understanding the status of co-infection could clarify the process of gastric carcinogenesis, and application of this knowledge for clinical purposes could facilitate diagnosis, risk management, and prevention.

1 February 2023 in Future Science OA
Verified
Journal Article
Open access
BABerjas Abumsimir
Berjas Abumsimir
TATalal S Al-Qaisi
Talal S Al-Qaisi

27 April 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
ITIkram Tiabi
Ikram Tiabi
YEYoussef Ennaji
Youssef Ennaji
BABerjas Abumsimir
Berjas Abumsimir
ALAbdelilah Laraqui
Abdelilah Laraqui
KEKhalid Ennibi
Khalid Ennibi
MEMOULAY MUSTAPHA ENNAJI
MOULAY MUSTAPHA ENNAJI
Background: B-Raf proto-oncogene has been found in a variety of neoplasms. BRAF stimulation can promote tumour proliferation through the activation of the MAP/ERK kinase pathway. This study aimed to determine the germline spectra of BRAF and the association with pathological criteria of prostate tumours. Methods: Fifty blood samples from men treated with prostate cancer were analyzed for BRAF germline mutations and confirmed by Sanger sequencing, in addition, to establishing the frequencies and clinical correlations of frequent mutations in the BRAF gene for both exon 11 and exon 15. The frequency and distribution of high-frequency mutations were analyzed according to the pathological criteria of the patients. Results: Frameshift mutations: c.1628_1629insA and c.1624_1625insT with a frequency of (46%) and (18%), respectively, Nonsense mutations: c.1181C>A (p.Ser394Ter) was detected in one patient, missense mutations: c.1226A>G (p.Gln409Arg), c.1270T>C (p.Trp424Arg), c.1270_1271delins2 (p.Trp424Leu), with a frequency of (4%) were detected. There was no significant difference between mutation carriers and non-carriers regarding medical and surgical history, but prostate-specific antigen concentration was significantly different between the two groups. Conclusion: The results of this study elucidate the presence and involvement of germline mutations in prostate cancer, which could serve as a potential indicator for the diagnosis and therapeutic management of prostate cancer in the population studied.

28 February 2024 in Future Science OA
Verified
Journal Article
Open access
BABerjas Abumsimir
Berjas Abumsimir
TATalal Al-Qaisi
Talal Al-Qaisi
SZSima Zein
Sima Zein

5 July 2023 in Future Science OA
Verified
Journal Article
Open access
TATalal Al-Qaisi
Talal Al-Qaisi
BABerjas Abumsimir
Berjas Abumsimir

1 February 2020 in Meta Gene
Verified
Journal Article
Closed access
BABerjas Abumsimir
Berjas Abumsimir
MMMohammed Mrabti
Mohammed Mrabti
ALAbdelilah Laraqui
Abdelilah Laraqui
AAAhmed Ameur
Ahmed Ameur
SKSaad Ibnsouda Koraishi
Saad Ibnsouda Koraishi
MEMOULAY MUSTAPHA ENNAJI
MOULAY MUSTAPHA ENNAJI